Benzinga | Mar 1, 2021 11:41AM EST

Wedbush Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $88

Wedbush analyst Liana Moussatos maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $106 to $88.